HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Cancer Female|Breast Cancer, Male|Invasive Breast Cancer|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma|Stage II Breast Cancer|Stage III Breast Cancer
Interventions: BIOLOGICAL: Dendritic Cell Vaccine (DC1)|DRUG: Neoadjuvant Chemotherapy|PROCEDURE: Curative Surgery
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: United States Department of Defense